UPDATE - Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease
June 14 2019 - 1:44PM
Mesoblast Limited (NASDAQ: MESO; ASX: MSB), global leader in
cellular medicines for inflammatory diseases, today announced that
it will host a virtual symposium on Monday, June 17 to discuss
Mesoblast’s product candidate, remestemcel-L, in steroid refractory
acute graft versus host disease (aGVHD) in children, and to include
Dr. Susan E. Prockop, a key opinion leader with significant
expertise and experience in treating pediatric patients with this
life threatening disease. Dr. Prockop is a pediatric oncologist
specializing in bone marrow and stem cell transplantation at
Memorial Sloan Kettering Cancer Center in New York. She also served
as an investigator in Mesoblast’s recent remestemecel-L study in
pediatric patients with steroid refractory aGVHD.
The webcast event will feature a presentation by
Dr. Prockop who will address the current management and treatment
options for patients with aGVHD. She will also discuss her
experiences with remestemcel-L in patients with steroid refractory
aGVHD. Mesoblast senior management will discuss the potential
market and commercial opportunities for remestemcel-L should it
receive approval from the US Food and Drug Administration (FDA).
The Company has agreement from the FDA for submission of a rolling
Biologics License Application (BLA) for remestemcel-L in the
treatment of aGVHD in children, for which the Company filed the
first component of in May of 2019.
Interested parties may access the event on
Monday, June 17 at 9:00am EDT (11:00 pm AEST) by dialing (866)
939-3921 (US); 1 800 507 265 (Australia) or 0808 238 9578 (UK)
using the confirmation code 48733893.
The webcast can be accessed live here:
http://www.wsw.com/webcast/cc/meso. The webcast will also be
accessible on the Investors & Media section of the Company’s
website at www.mesoblast.com.
About Steroid-refractory Acute Graft
Versus Host Disease Steroid-refractory acute graft
versus host disease (aGVHD) is a life-threatening complication of a
bone marrow transplant in patients primarily being treated for
blood cancers. There are more than 30,000 allogeneic bone marrow
transplants performed globally, with 20-25% occurring in children.
Currently, there are no approved products for aGVHD in children
outside Japan, where Mesoblast licensee JCR Pharmaceuticals markets
TEMCELL®1 HS Inj. for both children and adults with aGVHD.
About Mesoblast Mesoblast
Limited (ASX:MSB; Nasdaq:MESO) has leveraged its proprietary
technology platform to establish a broad portfolio of late-stage
allogeneic (off-the-shelf) product candidates with three product
candidates in Phase 3 trials – acute graft versus host disease,
chronic heart failure and chronic low back pain due to degenerative
disc disease. Through a proprietary process, Mesoblast selects rare
mesenchymal lineage precursor and stem cells from the bone marrow
of healthy adults and creates master cell banks, which can be
industrially expanded to produce thousands of doses from each donor
without the need for tissue matching. Mesoblast has facilities in
Melbourne, New York, Singapore and Texas and is listed on the
Australian Securities Exchange (MSB) and on the Nasdaq (MESO).
www.mesoblast.com
1. TEMCELL® HS Inj. is a registered trademark of
JCR Pharmaceuticals Co. Ltd.
Forward-Looking Statements This
announcement includes forward-looking statements that relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements
to differ materially from any future results, levels of activity,
performance or achievements expressed or implied by these
forward-looking statements. We make such forward-looking statements
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
Forward-looking statements should not be read as a guarantee of
future performance or results, and actual results may differ from
the results anticipated in these forward-looking statements, and
the differences may be material and adverse. Forward-looking
statements include, but are not limited to, statements about the
timing, progress and results of Mesoblast’s preclinical and
clinical studies; Mesoblast’s ability to advance product candidates
into, enroll and successfully complete, clinical studies; the
timing or likelihood of regulatory filings and approvals; and the
pricing and reimbursement of Mesoblast’s product candidates, if
approved. You should read this press release together with our risk
factors, in our most recently filed reports with the SEC or on our
website. Uncertainties and risks that may cause Mesoblast’s actual
results, performance or achievements to be materially different
from those which may be expressed or implied by such statements,
and accordingly, you should not place undue reliance on these
forward-looking statements. We do not undertake any obligations to
publicly update or revise any forward-looking statements, whether
as a result of new information, future developments or
otherwise.
For further information, please contact:
Julie MeldrumCorporate CommunicationsT: +61 3
9639
6036E: julie.meldrum@mesoblast.com
Schond GreenwayInvestor RelationsT: +1 212 880
2060E: schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From May 2024 to Jun 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2023 to Jun 2024